Fietta A M, Merlini C, Uccelli M, Gialdroni Grassi G, Grassi C
Chair of Chemotherapy, University of Pavia, IRCCS, Policlinico S. Matteo, Italy.
Respiration. 1992;59(5):253-8. doi: 10.1159/000196069.
The immunological and clinical effects of two oral treatment schedules of RU 41740 (standard for 3 months vs. long-term for 6 months) were assessed in 40 patients with chronic bronchitis by a controlled, double-blind, randomized trial. Both treatments significantly improved phagocytosis index of both neutrophils and monocytes, and the phagocytosis frequency and the candidacidal activity of neutrophils, showing the maximum stimulation at the end of the third course of treatment. Both treatment schedules reduced the number and the duration of infectious exacerbations of chronic bronchitis with respect to those observed in the corresponding period of the previous year. However, no significant difference between standard and long-term treatment with RU 41740 was found with respect to the immunological and clinical effect and tolerability.
通过一项对照、双盲、随机试验，对40例慢性支气管炎患者评估了RU 41740两种口服治疗方案（标准治疗3个月与长期治疗6个月）的免疫和临床效果。两种治疗均显著改善了中性粒细胞和单核细胞的吞噬指数，以及中性粒细胞的吞噬频率和杀念珠菌活性，在第三个疗程结束时显示出最大刺激作用。两种治疗方案均使慢性支气管炎感染性加重的次数和持续时间相较于上一年同期有所减少。然而，在免疫和临床效果以及耐受性方面，未发现RU 41740标准治疗与长期治疗之间存在显著差异。
